Wael A. Harb

Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

Denise A. Yardley, Shinzaburo Noguchi, Kathleen I. Pritchard et al. · Advances in Therapy · 2013 · 520 citations · Full text

Medicine, Oncology, Pharmacology +17

PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer

R. Wendel Naumann, Robert L. Coleman, Robert A. Burger et al. · Journal of Clinical Oncology · 2013 · 233 citations

Medicine, Oncology, Pharmacology +16

Mutational Analysis of Circulating Tumor Cells Using a Novel Microfluidic Collection Device and qPCR Assay

Wael A. Harb, Andrea Fan, Tony Tran et al. · Translational Oncology · 2013 · 207 citations · Full text

Medicine, Cell Biology, Oncology +16

A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179

Greg Andrew Durm, Salma K. Jabbour, Sandra K. Althouse et al. · Cancer · 2020 · 164 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Cristina Saura, José Á. García-Sáenz, Binghe Xu et al. · Journal of Clinical Oncology · 2014 · 137 citations

Medicine, Oncology, Pharmacology +16